Search ↗

Comparison

HGH Fragment 176-191 vs Semaglutide

HGH Fragment 176-191 is IGF & growth factors; Semaglutide is GLP-1 & incretins. They are compared here because they are frequently considered against each other, not because they act alike.

On published evidence alone, Semaglutide is the better documented of the two (regulator approved). That is a statement about the state of the literature, not a recommendation.

HGH Fragment 176-191 Semaglutide
Class IGF & growth factors GLP-1 & incretins
Evidence Preliminary human Regulator approved
Human trials ~3 ~90
Half-life ~30 minutes ~7 days
Reported range 250-500 mcg 250 mcg - 2.4 mg
Frequency 1-2x daily, fasted Once weekly, titrated over 16+ weeks
Routes Subcutaneous Subcutaneous, Oral
FDA approved No Yes
Research use only Yes No
Banned in sport Yes No
Studied for Fat loss research, Body composition Type 2 diabetes, Chronic weight management, Cardiovascular risk reduction
Reported side effects Injection-site reactions, Headache, Transient fatigue Nausea, Vomiting, Diarrhoea, Constipation, Abdominal pain, Injection-site reactions

HGH Fragment 176-191

This 16-residue fragment corresponds to the C-terminus of human growth hormone and reproduces the lipolytic and anti-lipogenic activity of the full molecule. Because it lacks the regions responsible for receptor-mediated growth signalling, it does not raise IGF-1 or produce the glucose intolerance associated with exogenous hGH. Human data for the fragment itself is thin, and the best-studied derivative is AOD-9604, which failed to separate from placebo on weight loss in its phase IIb trial.

Semaglutide

Semaglutide is a GLP-1 analog with roughly 94% homology to native GLP-1, modified by substituting alpha-aminoisobutyric acid at position 8 to resist DPP-4 cleavage and by attaching a C18 fatty diacid chain that binds albumin. Together these give a half-life of about a week, allowing once-weekly dosing. It lowers blood glucose through glucose-dependent insulin secretion and glucagon suppression, slows gastric emptying, and acts on hypothalamic appetite centres to reduce energy intake. The STEP trial programme reported mean weight reductions near 15% of body weight at 68 weeks on 2.4 mg weekly.

HGH Fragment 176-191 vs Semaglutide: common questions

What is the difference between HGH Fragment 176-191 and Semaglutide?

HGH Fragment 176-191 is IGF & growth factors and Semaglutide is GLP-1 & incretins, so they act on different pathways. HGH Fragment 176-191: The C-terminal fragment of human growth hormone that carries its fat-metabolising activity without the growth-promoting portion. Semaglutide: A long-acting GLP-1 receptor agonist and the compound that reset expectations for pharmacological weight loss.

Which has stronger evidence, HGH Fragment 176-191 or Semaglutide?

Semaglutide has the stronger evidence base (regulator approved, about 90 human studies) compared with HGH Fragment 176-191 (preliminary human).

Are HGH Fragment 176-191 and Semaglutide FDA approved?

Only Semaglutide is FDA approved (Type 2 diabetes mellitus (Ozempic, Rybelsus); Chronic weight management (Wegovy); Cardiovascular risk reduction in established CVD with overweight or obesity; Reducing the risk of kidney disease progression and cardiovascular death in adults with type 2 diabetes and chronic kidney disease (Ozempic, January 2025); Noncirrhotic MASH with moderate to advanced liver fibrosis in adults (Wegovy, accelerated approval August 2025)). HGH Fragment 176-191 is not approved for any indication.

References

Regulatory and primary sources

  1. PubChem compound record (CID 172966176) ↗ · structure, identifiers, synonyms
  2. WADA Prohibited List ↗ · current year
  3. FDA: Unapproved drugs and "research use only" products ↗ · regulatory status of non-approved products
  4. CAS Registry Number 66004-57-7 ↗ · chemical identity
  5. PubChem compound record (CID 56843331) ↗ · structure, identifiers, synonyms
  6. DailyMed: FDA-approved labeling for Semaglutide ↗ · indications, dosing, warnings as approved
  7. FDA Drugs@FDA database ↗ · approval history
  8. CAS Registry Number 910463-68-2 ↗ · chemical identity

Published literature

  1. Rahman OF, Lee SJ, Seeds WA. Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.J Am Acad Orthop Surg Glob Res Rev 2026.PubMed 41490200 · doi:10.5435/JAAOSGlobal-D-25-00236
  2. Wilding J. AOD-9604 Metabolic.Curr Opin Investig Drugs 2004.PubMed 15134286
  3. Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.Sports Med 2026.PubMed 41966639 · doi:10.1007/s40279-026-02437-0
  4. Jensen MD. Potential role of new therapies in modifying cardiovascular risk in overweight patients with metabolic risk factors.Obesity (Silver Spring) 2006.PubMed 16931496 · doi:10.1038/oby.2006.294
  5. Halford JC. Obesity drugs in clinical development.Curr Opin Investig Drugs 2006.PubMed 16625817
  6. Khan A, Raza S, Khan Y, et al.. Current updates in the medical management of obesity.Recent Pat Endocr Metab Immune Drug Discov 2012.PubMed 22435392 · doi:10.2174/187221412800604644
  7. Thevis M, Schänzer W. Analytical approaches for the detection of emerging therapeutics and non-approved drugs in human doping controls.J Pharm Biomed Anal 2014.PubMed 24906629 · doi:10.1016/j.jpba.2014.05.020
  8. Zieba R. [Obesity: a review of currently used antiobesity drugs and new compounds in clinical development].Postepy Hig Med Dosw (Online) 2007.PubMed 17971763
  9. Wilding JPH, Batterham RL, Davies M, et al.. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension.Diabetes Obes Metab 2022.PubMed 35441470 · doi:10.1111/dom.14725
  10. Rubino DM, Greenway FL, Khalid U, et al.. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.JAMA 2022.PubMed 35015037 · doi:10.1001/jama.2021.23619
  11. Wilding JPH, Batterham RL, Calanna S, et al.. Once-Weekly Semaglutide in Adults with Overweight or Obesity.N Engl J Med 2021.PubMed 33567185 · doi:10.1056/NEJMoa2032183
  12. Rubino D, Abrahamsson N, Davies M, et al.. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial.JAMA 2021.PubMed 33755728 · doi:10.1001/jama.2021.3224
  13. Aronne LJ, Horn DB, le Roux CW, et al.. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.N Engl J Med 2025.PubMed 40353578 · doi:10.1056/NEJMoa2416394
  14. Wharton S, Freitas P, Hjelmesæth J, et al.. Once-weekly semaglutide 7·2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial.Lancet Diabetes Endocrinol 2025.PubMed 40961952 · doi:10.1016/S2213-8587(25)00226-8
  15. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al.. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.N Engl J Med 2023.PubMed 37952131 · doi:10.1056/NEJMoa2307563
  16. Frías JP, Davies MJ, Rosenstock J, et al.. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.N Engl J Med 2021.PubMed 34170647 · doi:10.1056/NEJMoa2107519

Literature retrieved from PubMed on October 16, 2026, favouring human studies and reviews. Numbered markers in the text show which paper supports which statement; uncited entries are background reading.

Read this first This page compares published reference data. It is not medical advice and not a recommendation to use either compound. Several compounds documented on this site are not approved for human use.